February 2021
-
Mary Jo Fidler, MD
Mary Jo Fidler, MD, is now Section Chief for Section of Medical Oncology at Rush Medical College. She has been on staff in medical oncology at RUSH since 2007. Dr. […]
-
Premonitions About Lung Cancer for the Next Decade
Daniel Kahneman, PhD, was awarded the Nobel Prize in 2002 for proving, among other things, that intuitions—even expert ones—fail and that formulas based on data fare better. Intuitions are more […]
-
Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer
HER2 can be aberrantly expressed in NSCLC, caused by its mutation and/or amplification.1 Like in breast cancer, patients with NSCLC with somatic HER2 mutations rarely show concurrent gene amplification, highlighting […]
-
Tepotinib Approved for MET Exon 14 Skipping Mutated Metastatic NSCLC
February 3, 2021—Tepotinib was approved for treatment of patients with metastatic NSCLC who harbor MET exon 14 skipping alterations. Approval was based on data from the VISION trial (NCT02864992). VISION, […]
-
IASLC GENERAL DISCLAIMER
All information and materials presented on or through IASLC’s websites, or made available or provided by or on behalf of IASLC during any webinar, seminar, or other event or activity, […]
-
Acute Admissions Rates for Lung Cancer Patients Up During Pandemic, Not Linked to COVID-19
Data from a single-center study in Scotland suggested that there were more patients with lung cancer admitted acutely with cancer, non-COVID-19-related illness during the COVID-19 pandemic. “Early and late lockdown […]
-
Modeling Analyses Show That Expansions in Lung Cancer Screening Guidelines to Better Capture Underrepresented Populations Still Need Work
Two abstracts presented at the 2020 World Conference on Lung Cancer shed light on how changes in current screening guidelines can influence lung cancer detection rates, specifically among underrepresented populations. […]
-
Young Investigators Awarded Grants to Study COVID-19 and Lung Cancer
Lung Ambition Alliance to award four new Junior Faculty Research Grants. Four early-career researchers have been selected to receive the Lung Ambition Alliance Junior Faculty Grants for the Study of […]
-
Lung Ambition Alliance: Stronger Together
The IASLC has formed an alliance with the Global Lung Cancer Coalition (GLCC), Guardant Health, and AstraZeneca to accelerate the pace of lung cancer survival worldwide. This collaborative effort—known as […]
-
Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?
Oncologists currently have three main therapeutic strategies to choose from when managing patients with advanced NSCLC who lack targetable mutations: immunotherapy alone, immunotherapy-immunotherapy combinations, or immunotherapy-chemotherapy combinations. So how does […]
View ILCN Archives
Provider Resources